Literature DB >> 24353905

Hereditary leukemia due to rare RUNX1c splice variant (L472X) presents with eczematous phenotype.

A Sorrell1, C Espenschied2, W Wang3, J Weitzel2, S Chu4, P Parker4, S Saldivar5, R Bhatia4.   

Abstract

Deleterious mutations in the RUNX1 gene cause hereditary leukemia due to a rare syndrome called Familial platelet Disorder with Associated Myeloid Malignancy (FPDMM). We describe the characteristics of a family with FPDMM due to a novel RUNX1 mutation (L472X), located in the most 3-prime end of the gene reported to date. Our 36-year old proband presented with incidentally detected thrombocytopenia and a family history suggestive of FPDMM. Contrary to previously described families, affected members of our kindred express an eczematous phenotype, reportedly most severe in members who develop leukemia. Pedigree analysis shows that the L472X mutation tracks with thrombocytopenia, acute leukemia, and eczema. The L472X mutation produces a stably expressed RUNX1 protein product with a corresponding decrease in wild type RUNX1 expression. Our data supports the inclusion of eczema in the FPDMM phenotype and suggests the possibility that the RUNX1 L472X mutant causes the type of dominant negative affect that is associated with an elevated risk of leukemia in FPDMM families.

Entities:  

Keywords:  FPDMM; L472X; RUNX1c isoform; eczema; hereditary leukemia

Year:  2012        PMID: 24353905      PMCID: PMC3864030          DOI: 10.4236/ijcm.2012.37110

Source DB:  PubMed          Journal:  Int J Clin Med        ISSN: 2158-284X


  42 in total

1.  DMDM: domain mapping of disease mutations.

Authors:  Thomas A Peterson; Asa Adadey; Ivette Santana-Cruz; Yanan Sun; Andrew Winder; Maricel G Kann
Journal:  Bioinformatics       Date:  2010-08-04       Impact factor: 6.937

2.  Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development.

Authors:  Yoko Fukushima-Nakase; Yoshinori Naoe; Ichiro Taniuchi; Hajime Hosoi; Tohru Sugimoto; Tsukasa Okuda
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

3.  Anticipation in familial leukemia.

Authors:  M Horwitz; E L Goode; G P Jarvik
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

Review 4.  Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML).

Authors:  Carolyn Owen
Journal:  Leuk Res       Date:  2009-08-19       Impact factor: 3.156

5.  Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.

Authors:  Dominique Bluteau; Laure Gilles; Morgane Hilpert; Iléana Antony-Debré; Chloe James; Najet Debili; Valerie Camara-Clayette; Orianne Wagner-Ballon; Veronique Cordette-Lagarde; Thomas Robert; Hugues Ripoche; Patrick Gonin; Sabina Swierczek; Josef Prchal; William Vainchenker; Remi Favier; Hana Raslova
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

6.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

7.  CBFA2, frequently rearranged in leukemia, is not responsible for a familial leukemia syndrome.

Authors:  R D Legare; D Lu; M Gallagher; C Ho; X Tan; G Barker; K Shimizu; M Ohki; N Lenny; S Hiebert; D G Gilliland
Journal:  Leukemia       Date:  1997-12       Impact factor: 11.528

8.  Decreased content and surface expression of alpha-granule membrane protein GMP-140 in one of two types of platelet alpha delta storage pool deficiency.

Authors:  B Lages; S J Shattil; D F Bainton; H J Weiss
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

9.  Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome.

Authors:  M C J Jongmans; R P Kuiper; C L Carmichael; E J Wilkins; N Dors; A Carmagnac; A Y N Schouten-van Meeteren; X Li; M Stankovic; E Kamping; H Bengtsson; E F P M Schoenmakers; A Geurts van Kessel; P M Hoogerbrugge; C N Hahn; P P Brons; H S Scott; N Hoogerbrugge
Journal:  Leukemia       Date:  2009-10-15       Impact factor: 11.528

Review 10.  Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.

Authors:  Peter Ganly; Logan C Walker; Christine M Morris
Journal:  Leuk Lymphoma       Date:  2004-01
View more
  8 in total

Review 1.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

2.  Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies.

Authors:  Maya Lewinsohn; Anna L Brown; Luke M Weinel; Connie Phung; George Rafidi; Ming K Lee; Andreas W Schreiber; Jinghua Feng; Milena Babic; Chan-Eng Chong; Young Lee; Agnes Yong; Graeme K Suthers; Nicola Poplawski; Meryl Altree; Kerry Phillips; Louise Jaensch; Miriam Fine; Richard J D'Andrea; Ian D Lewis; Bruno C Medeiros; Daniel A Pollyea; Mary-Claire King; Tom Walsh; Siobán Keel; Akiko Shimamura; Lucy A Godley; Christopher N Hahn; Jane E Churpek; Hamish S Scott
Journal:  Blood       Date:  2015-12-28       Impact factor: 22.113

Review 3.  Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).

Authors:  Anna L Brown; Christopher N Hahn; Hamish S Scott
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

4.  Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling.

Authors:  Dana C Bellissimo; Chia-Hui Chen; Qin Zhu; Sumedha Bagga; Chung-Tsai Lee; Bing He; Gerald B Wertheim; Martha Jordan; Kai Tan; G Scott Worthen; D Gary Gilliland; Nancy A Speck
Journal:  Blood Adv       Date:  2020-03-24

Review 5.  Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.

Authors:  Kristen E Schratz; Amy E DeZern
Journal:  Hematol Oncol Clin North Am       Date:  2020-01-06       Impact factor: 3.722

Review 6.  RUNX1 Mutations in Inherited and Sporadic Leukemia.

Authors:  Dana C Bellissimo; Nancy A Speck
Journal:  Front Cell Dev Biol       Date:  2017-12-20

7.  Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation.

Authors:  Rashmi Kanagal-Shamanna; Sanam Loghavi; Courtney D DiNardo; L Jeffrey Medeiros; Guillermo Garcia-Manero; Elias Jabbour; Mark J Routbort; Rajyalakshmi Luthra; Carlos E Bueso-Ramos; Joseph D Khoury
Journal:  Haematologica       Date:  2017-06-28       Impact factor: 9.941

8.  RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.

Authors:  Anna L Brown; Peer Arts; Catherine L Carmichael; Milena Babic; Julia Dobbins; Chan-Eng Chong; Andreas W Schreiber; Jinghua Feng; Kerry Phillips; Paul P S Wang; Thuong Ha; Claire C Homan; Sarah L King-Smith; Lesley Rawlings; Cassandra Vakulin; Andrew Dubowsky; Jessica Burdett; Sarah Moore; Grace McKavanagh; Denae Henry; Amanda Wells; Belinda Mercorella; Mario Nicola; Jeffrey Suttle; Ella Wilkins; Xiao-Chun Li; Joelle Michaud; Peter Brautigan; Ping Cannon; Meryl Altree; Louise Jaensch; Miriam Fine; Carolyn Butcher; Richard J D'Andrea; Ian D Lewis; Devendra K Hiwase; Elli Papaemmanuil; Marshall S Horwitz; Georges Natsoulis; Hugh Y Rienhoff; Nigel Patton; Sally Mapp; Rachel Susman; Susan Morgan; Julian Cooney; Mark Currie; Uday Popat; Tilmann Bochtler; Shai Izraeli; Kenneth Bradstock; Lucy A Godley; Alwin Krämer; Stefan Fröhling; Andrew H Wei; Cecily Forsyth; Helen Mar Fan; Nicola K Poplawski; Christopher N Hahn; Hamish S Scott
Journal:  Blood Adv       Date:  2020-03-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.